# L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

> **NCT06788756** · PHASE2,PHASE3 · RECRUITING · sponsor: **Moleculin Biotech, Inc.** · enrollment: 312 (estimated)

## Conditions studied

- Acute Myeloid Leukaemia (AML)

## Interventions

- **DRUG:** Placebo in combination with Cytarabine Injection
- **DRUG:** Liposomal Annamycin Injection in combination with Cytarabine Injection
- **DRUG:** Liposomal Annamycin Injection in combination with Cytarabine Injection
- **DRUG:** Liposomal Annamycin for Injection in combination with Cytarabine Injection.

## Key facts

- **NCT ID:** NCT06788756
- **Lead sponsor:** Moleculin Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2029-08
- **Final completion:** 2030-08
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06788756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06788756, "L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06788756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*